New perspectives in the second-line treatment of non squamous NSCLC patients

Results from a large Italian Lung Cancer Working Group

Diego Cortinovis, Vanesa Gregorc, Maria Rita Migliorino, Maria Ida Abate, Anna Manzo, Umberto Malapelle, Alessandro Morabito

Research output: Contribution to journalReview article

9 Citations (Scopus)

Abstract

Lung cancer is still considered a big killer among cancer diseases, due to high incidence and mortality rates. The newer frontiers of therapeutic development regard the discovery of oncogene driven tumours: however, the majority of NSCLC patients are wild type and they cannot be treated with targeted based agents. The recent positive results obtained with immunotherapy and with the combination of angiogenesis inhibitors and docetaxel, changed the therapeutic scenario of the second line therapy of non squamous NSCLC without actionable mutations. A major issue is currently the lack of predictive biomarkers that could help the oncologists in the choice of the best second-line treatment. Aim of this project was to define an optimal therapeutic pathway for patients with non-squamous NSCLC, through a working group of a large number of Italian lung cancer oncologists. Panellists have identified and discussed the more significant criteria in the second-line setting for a therapeutic decision between the combination of angiogenesis inhibitors plus chemotherapy or immunotherapy. Finally, they expressed their preference on each criterion, building a proposal of a decision-making tree for a second-line treatment of non-squamous NSCLC.

Original languageEnglish
Pages (from-to)35-41
Number of pages7
JournalCritical Reviews in Oncology/Hematology
Volume109
DOIs
Publication statusPublished - Jan 1 2017

Fingerprint

Lung Neoplasms
Angiogenesis Inhibitors
docetaxel
Immunotherapy
Therapeutics
Decision Trees
Oncogenes
Neoplasms
Decision Making
Biomarkers
Drug Therapy
Mutation
Mortality
Incidence

Keywords

  • Atezolizumab
  • Docetaxel
  • Nintedanib
  • Nivolumab
  • Non squamous NSCLC
  • Pembrolizumab
  • Ramucirumab
  • Second line therapy
  • Therapeutic strategy

ASJC Scopus subject areas

  • Hematology
  • Oncology
  • Geriatrics and Gerontology

Cite this

New perspectives in the second-line treatment of non squamous NSCLC patients : Results from a large Italian Lung Cancer Working Group. / Cortinovis, Diego; Gregorc, Vanesa; Migliorino, Maria Rita; Abate, Maria Ida; Manzo, Anna; Malapelle, Umberto; Morabito, Alessandro.

In: Critical Reviews in Oncology/Hematology, Vol. 109, 01.01.2017, p. 35-41.

Research output: Contribution to journalReview article

Cortinovis, Diego ; Gregorc, Vanesa ; Migliorino, Maria Rita ; Abate, Maria Ida ; Manzo, Anna ; Malapelle, Umberto ; Morabito, Alessandro. / New perspectives in the second-line treatment of non squamous NSCLC patients : Results from a large Italian Lung Cancer Working Group. In: Critical Reviews in Oncology/Hematology. 2017 ; Vol. 109. pp. 35-41.
@article{2490c769ed114095a7f7fef34cb81695,
title = "New perspectives in the second-line treatment of non squamous NSCLC patients: Results from a large Italian Lung Cancer Working Group",
abstract = "Lung cancer is still considered a big killer among cancer diseases, due to high incidence and mortality rates. The newer frontiers of therapeutic development regard the discovery of oncogene driven tumours: however, the majority of NSCLC patients are wild type and they cannot be treated with targeted based agents. The recent positive results obtained with immunotherapy and with the combination of angiogenesis inhibitors and docetaxel, changed the therapeutic scenario of the second line therapy of non squamous NSCLC without actionable mutations. A major issue is currently the lack of predictive biomarkers that could help the oncologists in the choice of the best second-line treatment. Aim of this project was to define an optimal therapeutic pathway for patients with non-squamous NSCLC, through a working group of a large number of Italian lung cancer oncologists. Panellists have identified and discussed the more significant criteria in the second-line setting for a therapeutic decision between the combination of angiogenesis inhibitors plus chemotherapy or immunotherapy. Finally, they expressed their preference on each criterion, building a proposal of a decision-making tree for a second-line treatment of non-squamous NSCLC.",
keywords = "Atezolizumab, Docetaxel, Nintedanib, Nivolumab, Non squamous NSCLC, Pembrolizumab, Ramucirumab, Second line therapy, Therapeutic strategy",
author = "Diego Cortinovis and Vanesa Gregorc and Migliorino, {Maria Rita} and Abate, {Maria Ida} and Anna Manzo and Umberto Malapelle and Alessandro Morabito",
year = "2017",
month = "1",
day = "1",
doi = "10.1016/j.critrevonc.2016.11.015",
language = "English",
volume = "109",
pages = "35--41",
journal = "Critical Reviews in Oncology/Hematology",
issn = "1040-8428",
publisher = "Elsevier Ireland Ltd",

}

TY - JOUR

T1 - New perspectives in the second-line treatment of non squamous NSCLC patients

T2 - Results from a large Italian Lung Cancer Working Group

AU - Cortinovis, Diego

AU - Gregorc, Vanesa

AU - Migliorino, Maria Rita

AU - Abate, Maria Ida

AU - Manzo, Anna

AU - Malapelle, Umberto

AU - Morabito, Alessandro

PY - 2017/1/1

Y1 - 2017/1/1

N2 - Lung cancer is still considered a big killer among cancer diseases, due to high incidence and mortality rates. The newer frontiers of therapeutic development regard the discovery of oncogene driven tumours: however, the majority of NSCLC patients are wild type and they cannot be treated with targeted based agents. The recent positive results obtained with immunotherapy and with the combination of angiogenesis inhibitors and docetaxel, changed the therapeutic scenario of the second line therapy of non squamous NSCLC without actionable mutations. A major issue is currently the lack of predictive biomarkers that could help the oncologists in the choice of the best second-line treatment. Aim of this project was to define an optimal therapeutic pathway for patients with non-squamous NSCLC, through a working group of a large number of Italian lung cancer oncologists. Panellists have identified and discussed the more significant criteria in the second-line setting for a therapeutic decision between the combination of angiogenesis inhibitors plus chemotherapy or immunotherapy. Finally, they expressed their preference on each criterion, building a proposal of a decision-making tree for a second-line treatment of non-squamous NSCLC.

AB - Lung cancer is still considered a big killer among cancer diseases, due to high incidence and mortality rates. The newer frontiers of therapeutic development regard the discovery of oncogene driven tumours: however, the majority of NSCLC patients are wild type and they cannot be treated with targeted based agents. The recent positive results obtained with immunotherapy and with the combination of angiogenesis inhibitors and docetaxel, changed the therapeutic scenario of the second line therapy of non squamous NSCLC without actionable mutations. A major issue is currently the lack of predictive biomarkers that could help the oncologists in the choice of the best second-line treatment. Aim of this project was to define an optimal therapeutic pathway for patients with non-squamous NSCLC, through a working group of a large number of Italian lung cancer oncologists. Panellists have identified and discussed the more significant criteria in the second-line setting for a therapeutic decision between the combination of angiogenesis inhibitors plus chemotherapy or immunotherapy. Finally, they expressed their preference on each criterion, building a proposal of a decision-making tree for a second-line treatment of non-squamous NSCLC.

KW - Atezolizumab

KW - Docetaxel

KW - Nintedanib

KW - Nivolumab

KW - Non squamous NSCLC

KW - Pembrolizumab

KW - Ramucirumab

KW - Second line therapy

KW - Therapeutic strategy

UR - http://www.scopus.com/inward/record.url?scp=85006341339&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85006341339&partnerID=8YFLogxK

U2 - 10.1016/j.critrevonc.2016.11.015

DO - 10.1016/j.critrevonc.2016.11.015

M3 - Review article

VL - 109

SP - 35

EP - 41

JO - Critical Reviews in Oncology/Hematology

JF - Critical Reviews in Oncology/Hematology

SN - 1040-8428

ER -